Fact CheckerSign in

NCT07436455Recruiting

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Source: ClinicalTrials.gov · Last updated 27 Feb 2026

Brief summary (registry, in English)

In patients who have undergone surgery for differentiated thyroid cancer and who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy, lesion detection is performed using neck ultrasonography, thorax CT, and F-18 FDG PET/CT. Diagnostic whole-body scanning with low-dose I-131 is not routinely recommended in follow-up due to its low sensitivity and specificity. F-18 TFB is a highly specific imaging agent for differentiated thyroid cancer, entering thyroid follicular epithelial cells via the sodium-iodide symporter (NIS), which is expressed on the cell surface and functions through a mechanism similar to that of I-131. As a PET radiotracer, F-18 TFB has been shown to be superior to I-131 in previous studies. The primary aim of this study is to comparatively evaluate the role of F-18 TFB PET/CT versus the standard imaging modality F-18 Fluorodeoxyglucose (FDG) PET/CT in lesion detection in patients with differentiated thyroid cancer who demonstrate elevated serum Tg and/or ATg levels during follow-up after radioactive iodine therapy. The secondary aims are to investigate the factors predicting F-18 TFB PET/CT positivity and to assess the relationship between the semi-quantitative and quantitative parameters derived from F-18 TFB PET/CT and serum thyroglobulin (Tg) and anti-thyroglobulin (ATg) levels.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
50 (estimated)
First submitted
15 Feb 2026
Start date
1 Nov 2025
Primary completion date
1 Aug 2026
Lead sponsor
Ankara University
NCT number
NCT07436455

What you commit to

  • Study type: Interventional
  • Planned participants: 50
  • From 1 Nov 2025 to the primary completion date, 1 Aug 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Failure to provide written informed consent

Age

  • Age under 18 years

Other

  • Pregnancy or breastfeeding

Who the study is looking for

  • Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy
  • Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up
  • Negative or equivocal I-131 whole-body scan findings
  • Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status)
  • Giving written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hacettepe University Medical School Nuclear Medicine Department
Coordinator of this site? Confirm its status
AnkaraTurkey (Türkiye)Recruiting
Ankara University Medical School Nuclear Medicine Department
Coordinator of this site? Confirm its status
AnkaraTurkey (Türkiye)Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.